Who can participate?
Children and teens 6 to 17 years old with asthma who:
- Have had 2 or more asthma attacks in the last year
- Are taking a daily inhaled medication
What will happen in the study?
This study includes 33 study visits at Cincinnati Children’s over a 16-month period and up to 3 visits when your child has a cold.
Here are some of the things that will happen in this study:
We will ask you questions about your child’s health.
Your child will:
- Complete breathing tests
- Have an allergy skin test
- Submit blood, urine and nasal samples
- Be randomized to either receive the study drug, Dupilumab, or a placebo (inactive) shot
The study team will ask you to call if your child starts to show signs of a cold and bring them in for a “cold” visit. The purpose of these visits is to collect samples soon after his/her cold starts.
Parents or guardians interested in having their child participate will be given a consent form that thoroughly explains all of the details of the study. A member of the study staff will review the consent form with you and will be sure that all of your questions are answered.
What are the good things that can happen from this research?
Your child may directly benefit by receiving asthma care from an asthma specialist. You will receive information about your child’s breathing and allergen tests, as well as information about taking care of your child’s asthma.
Your child’s asthma and rhinitis may or may not improve while in this study, but he/she will be followed closely during the study.
Overall, the information we learn from this study may lead to study doctors having a better understanding of whether dupilumab helps children to have fewer asthma attacks.